Results 201 to 210 of about 509,314 (341)
Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?
Pediatric drug development has achieved remarkable success in the last 20 years with over 1,000 products studied in pediatric patients. This success has been driven in part by an increased understanding of pediatric disease processes. The aspect that has been largely overlooked is the potential adverse effect of new drugs on pediatric developmental ...
Gilbert J. Burckart +6 more
wiley +1 more source
Nitazoxanide and nonsteroidal anti-inflammatory drugs (NSAIDs): unveiling the connection in immediate hypersensitivity cross-reactions. [PDF]
Feodrippe ALO +4 more
europepmc +1 more source
Treatment of iron deficiency anemia: practical considerations [PDF]
Rampton, D, Taylor, S
core +1 more source
RORγt‐APCs: The New Masters of Oral Tolerance
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley +1 more source
Examination of HLA-DRB1*15-linked candidate antigens in Still's disease with and without lung disease and features of drug hypersensitivity. [PDF]
Kobrin DM +11 more
europepmc +1 more source
A Mutation in the Intrinsivally Disordered Fragment of SK2 Channel Confers Ca2+ Hypersensitivity [PDF]
Young Woo Nam +5 more
openalex +1 more source
Abstract Background Integrin is an αβ heterodimeric receptor to the extracellular matrix; its binding to the matrix recruits focal adhesions to two NPxY motifs, the tyrosine phosphorylation sites in the cytoplasmic domain. Studies found that replacing tyrosines (Y) with phenylalanines (F) in the motif of β1 integrin displayed little developmental or ...
Josh Haram Bumm +7 more
wiley +1 more source
Case Report: Late Hypersensitivity Reaction to Hydroxyurea in a Patient With Myeloproliferative Disorder. [PDF]
Kahlon N +5 more
europepmc +1 more source

